Latigo Biotherapeutics Q3 net loss narrows 16% to $20.95 million
LTGO•Latigo Biotherapeutics’ third-quarter net loss narrowed 16% year over year to $20.95 million. Cash and cash equivalents were $401.2 million at September 30, expected to fund operations into 2029.
1. Quarterly results and trials
Latigo Biotherapeutics’ third-quarter 2026 net loss narrowed 16% year over year to $20.95 million. Research and development expenses fell 21% to $17.5 million, while general and administrative expenses more than doubled to $5.43 million. The company had $401.2 million in cash and cash equivalents at September 30, expected to fund operations into 2029. Onzotrigine’s Phase 3 bunionectomy and open-label safety trials remain on track to start, with topline results expected in the second half of 2027; results from the ongoing Phase 2 LTG-321 chronic-pain trial are also expected then.
